Bio-Rad Laboratories

Global Chromatography Market Expected to Reach USD 10.5 Billion in 2023 with 5.5% CAGR Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, September 6, 2023
Other Science, Science, Bio-Rad Laboratories, Partnership, Food, Pyrosequencing, Waters, Waters Corporation, Biotechnology, COVID-19, Chromatography, Thermo Fisher Scientific, Type, USD, Compound annual growth rate, PerkinElmer, Name, COVID-19 vaccine, Acquisition, Patent, Laboratory, Sartorius, Agilent Technologies, Medicine, Drug discovery, Growth, Applied science, Valmet, Pall Corporation, HPLC, Automation, Fine chemical, Retail, Vaccine

The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.

Key Points: 
  • The global landscape of chromatography is set for a dynamic transformation, with an estimated market value of USD 10.5 billion in 2023.
  • Encompassing the chromatography instrumentation market, including liquid chromatography systems, gas chromatography systems, gel permeation chromatography, and more, along with the chromatography consumables market, this industry is poised to achieve a Compound Annual Growth Rate (CAGR) of 5.5% during the forecast period.
  • These include liquid chromatography systems, gas chromatography systems, gel permeation chromatography, supercritical fluid chromatography, and a range of chromatography consumables like chromatography resins and columns.
  • Market Analysis: The global chromatography market is estimated to reach USD 10.5 billion in 2023, with a projected CAGR of 5.5%.

Driving Precision Medicine: Rising Demand for Single Cell Analysis Propels Global Market Growth to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 5, 2023
COVID-19, Research, Genetics, Diabetes, Cardiology, Stem Cells, Biotechnology, Health, Science, Oncology, Bio-Rad Laboratories, Prevalence, Investment, SARS-CoV-2, Genomics, Cancer, Single-cell analysis, Medicine, Cell, Danaher Corporation, Competition, Becton, Dickinson and Company headquarters, Huntingdon, Compound annual growth rate, Neuroscience, Promega, NHLBI, HIV disease progression rates, Thermo Fisher Scientific, Application, Chronic condition, Consumables, Flow cytometry, Conditional sentence, Growth, Merck, Mindful Scientific Inc., Safety, Disease, Government, Pharmaceutical industry, Vaccine, Medical imaging, Illumina

The Global Single Cell Analysis Market is expected to experience substantial growth with a steady Compound Annual Growth Rate (CAGR) during the period of 2024 to 2028.

Key Points: 
  • The Global Single Cell Analysis Market is expected to experience substantial growth with a steady Compound Annual Growth Rate (CAGR) during the period of 2024 to 2028.
  • The growth of genomic and proteomic technologies has significantly influenced the expansion of the global single cell analysis market.
  • Chronic diseases, including cancer, cardiovascular conditions, and diabetes, are significant drivers of the global single cell analysis market.
  • Government funding plays a pivotal role in the growth of the global single cell analysis market.

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference

Retrieved on: 
Monday, August 28, 2023
Biotechnology, Pharmaceutical, Health, Research, Conference, NYSE, Bio-Rad Laboratories, Pharmaceutical industry, Rare-earth element

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time).

Global In-Vitro Diagnostics Market Report 2023-2028: Rising Demand for Automated IVD Systems in Hospitals & Laboratories - ResearchAndMarkets.com

Retrieved on: 
Monday, August 14, 2023
Infectious Diseases, Health, Other Health, Infection, Hepatitis, Laboratory, Prevalence, Medicine, Siemens Healthineers, Bio-Rad Laboratories, Hospital, Tuberculosis, BioMérieux, IVD, Conditional sentence, Growth, Pneumonia, Porter's five forces analysis, Medical device, Qiagen

The "In-Vitro Diagnostics Market: Trends, Opportunities and Competitive Analysis 2023-2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "In-Vitro Diagnostics Market: Trends, Opportunities and Competitive Analysis 2023-2028" report has been added to ResearchAndMarkets.com's offering.
  • The global in-vitro diagnostics market is expected to witness a promising future, with opportunities in the hospitals, laboratories, and home care end-use industries.
  • The market is projected to reach an estimated value of $127.3 billion by 2028, growing at a CAGR of 5% from 2023 to 2028.
  • The major drivers of this growth are the increasing prevalence of chronic diseases and the rising demand for automated IVD systems in hospitals and laboratories to ensure accurate, error-free, and efficient diagnoses.

Bio-Rad Reports Second-Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
Research, Pharmaceutical, Medical Devices, Infectious Diseases, Clinical Trials, Science, Biotechnology, Stem Cells, Medical Supplies, Other Science, Health, Diabetes, Table, Bank statement, GAAP, COVID, Forecasting, Bio-Rad Laboratories, Acquisition, Nature, Webcast, Growth, EPS, DIGITAL, Bank, Insurance, Life insurance

A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.

Key Points: 
  • A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
  • Management will discuss the company’s second quarter 2023 results and financial outlook in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) on August 3, 2023.
  • There are limitations in using non-GAAP financial measures because the non-GAAP financial measures are not prepared in accordance with generally accepted accounting principles and may be different from non-GAAP financial measures used by other companies.
  • The non-GAAP financial measures are limited in value because they exclude certain items that may have a material impact on our reported financial results.

Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement

Retrieved on: 
Wednesday, July 26, 2023
QIAGEN, QGEN, Bio-Rad Laboratories, District court, Patent, Douglas v. U.S. District Court ex rel Talk America, NYSE, PCR, Pharmaceutical industry, Television

Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Key Points: 
  • Hercules, Calif., and Venlo, the Netherlands, July 26, 2023 (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
  • The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.

Bio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing Agreement

Retrieved on: 
Wednesday, July 26, 2023
Stem Cells, Medical Supplies, Biotechnology, Diabetes, Health, Pharmaceutical, Medical Devices, Research, Genetics, Science, Clinical Trials, QIAGEN, QGEN, Bio-Rad Laboratories, District court, Patent, Douglas v. U.S. District Court ex rel Talk America, NYSE, PCR, Pharmaceutical industry

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230726552882/en/
    The settlement provides for a cross-licensing agreement between Bio-Rad and QIAGEN granting each company mutual rights to their respective digital PCR technologies.

Bio-Rad Announces New Share Repurchase Program

Retrieved on: 
Thursday, July 20, 2023
Diabetes, Other Health, Finance, Stem Cells, Pharmaceutical, Professional Services, Medical Devices, Infectious Diseases, Clinical Trials, Science, Biotechnology, Other Science, Health, Research, Medical Supplies, Share repurchase, NYSE, Bio-Rad Laboratories, Management

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock.
  • The Company previously announced on June 5, 2023, that it had completed the repurchase of all of its common stock authorized under the prior share repurchase program approved by the Company’s board of directors.
  • Repurchases under the new share repurchase program may be made at management's discretion from time to time on the open market or through privately negotiated transactions.
  • The new share repurchase program has no time limit and may be suspended or discontinued at any time.

Bio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023

Retrieved on: 
Monday, July 10, 2023
Stem Cells, Medical Supplies, Biotechnology, Health, Pharmaceutical, Health Technology, Medical Devices, Research, Hospitals, Science, Clinical Trials, Webcast, NYSE, Bio-Rad Laboratories

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market.
  • Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
  • From outside the U.S., participants can join the call via the Audience Entry URL , access code: 94809387.
  • A live webcast of the conference call will also be available in the "Investor Relations" section of the company’s website under "Events & Presentations" at investors.bio-rad.com .

Bio-Rad Publishes Corporate Sustainability Report for 2022

Retrieved on: 
Monday, July 10, 2023
Research, Professional Services, Pharmaceutical, Sustainability, Medical Devices, Environment, DEI (Diversity, Equity and Inclusion), Science, Biotechnology, Stem Cells, Medical Supplies, Health, Historically black colleges and universities, Ethics, Electricity, Sustainability accounting, GRI, University, NYSE, Carbon, Sustainability Accounting Standards Board, Bio-Rad Laboratories, Renewable energy

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainability report for fiscal year ended December 31, 2022.

Key Points: 
  • Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainability report for fiscal year ended December 31, 2022.
  • The report has been prepared with reference to the Global Reporting Initiative (GRI) 2021 Standards and in alignment with the Sustainability Accounting Standards Board (SASB).
  • “During 2022, we expanded our corporate sustainability reporting and disclosures in alignment with SASB guidelines,” said Norman Schwartz, Bio-Rad’s Chief Executive Officer.
  • “While we made meaningful progress on some of our long-term sustainability goals, we see room for continued improvement in other areas.